Patients’ Characteristics
| Characteristic | Data |
|---|---|
| Patients | 27 (100%) |
| Age (y) | 67.8 ± 8.8 (49.0–82.0) |
| Initial treatment | Radical prostatectomy: 25/27 (93%); radiation therapy: 2/27 (7%) |
| Initial Gleason score | 7: 18/27 (66.7%); 8: 1/27 (3.7%); 9: 8/27 (29.6%) |
| PSA (ng/mL) | 3.5 ± 3.9 (0.3–13.5) |
| PSA doubling time (mo) | 6.4 ± 5.2 (1.2–22.4)* |
| 68Ga-NeoB | |
| Injected activity (MBq) | 198.1 ± 25.5 (145.1–245.6) |
| Uptake time (min) | 49.7 ± 7.2 (43–77) |
| Duration of PET/MRI (min) | 58.5 ± 4.5 (42–66) |
| Delay to pelvic PET/MRI (min) | 35.9 ± 5.4 (21–46) |
| 68Ga-PSMA-R2 | |
| Injected activity (MBq) | 186.1 ± 29.2 (108.4–228.6) |
| Uptake time (min) | 47.0 ± 2.8 (44–55) |
| Duration of PET/MRI (min) | 58.1 ± 3.2 (52–65) |
| Delay to pelvic PET/MRI (min) | 37.4 ± 4.5 (29–54) |
| Time between scans (d) | 11.0 ± 15.2 (1–72) |
↵* Three patients showed PSA persistence after radical prostatectomy.
Qualitative data are number and percentage; continuous data are mean ± SD, followed by range in parentheses.